The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than defendants had led investors and analysts to believe; (ii) defendants overstated the financial prospects of the Company's products to treat opioid use disorders and serious mental illnesses, SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (iii) defendants knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY 2024 net revenue guidance, including its FY 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; (iv) defendants knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to cease all sales and marketing activities related to PERSERIS; and (v) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Indivior purchased or acquired during the class period listed above.
If you suffered a loss in Indivior during the relevant time frame, you have until October 01, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
